Xencor Plans Pivotal Study of XmAb819 in Advanced Kidney Cancer in 2027

PUBT · 2d ago
Xencor Plans Pivotal Study of XmAb819 in Advanced Kidney Cancer in 2027
  • Xencor will present Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma at ESMO on October 25, 2026.
  • Intravenous expansion cohorts are evaluating doses to support selection for a planned Phase 3 pivotal trial.
  • A registration-enabling monotherapy study in advanced clear cell renal cell carcinoma is planned for 2027.
  • A webcast to discuss the results is scheduled for October 26 at 7 a.m. EDT.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xencor Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019387869) on October 19, 2026, and is solely responsible for the information contained therein.